Cecília Menezes Farinasso
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Cecília Menezes Farinasso has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
- Roberta Borges Silva
Hospital Sírio-Libanês (HSL), São Paulo - SP, Brazil
5 shared publications - Ana Luiza Cabrera Martimbianco
Universidade Metropolitana de Santos
2 shared publications - Camila Monteiro Cruz
Hospital Sírio-Libanês (HSL), São Paulo - SP, Brazil
2 shared publications - Camile Giaretta Sachetti
Graduate Program for Collective Health, Faculty of Health Sciences, University of Brasilia (UnB), Brasilia, Brazil; Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, Brazil
2 shared publications - Carolina de Oliveira Cruz Latorraca
Hospital Sírio-Libanês (HSL), São Paulo - SP, Brazil; Centro Universitário São Camilo (CUSC), São Paulo - SP, Brazil
2 shared publications - Daniela Fortunato Rêgo
Ministério dos Direitos Humanos e da Cidadania Brasília Distrito Federal Brazil
2 shared publications
Latest Publications
- Open Access
- 4 August 2026
- Published by HTA Unit - Inova Medical in HTA Journal
- Vol. 1 (1) , 32-40
Use of indirect comparison in technology assessment in Brazilian supplementary health: meta-research
Introduction: Technologies already covered in health systems are the ideal comparators in the HTA process of new technologies, making a particular local challenge the finding of these specific head-to-head studies. In their absence, indirect comparisons are presented as alternatives, but the extent and characteristics of use are unknown. Objective: This study aims to quantify the use and characteristics of indirect comparison methods in reports of a Brazilian HTA agency. Methodology: A meta-research was conducted to analyze the frequency of use of different indirect comparison methods from the perspective of Brazil’s supplementary health system, and characteristics such as frequency of incorporation and preliminary recommendation, type of method, certainty-of-evidence assessment tool used, technology type, major clinical area, and budget impact of incorporation. The protocol was registered prospectively and is available at https://doi.org/10.17605/OSF.IO/3V8YP. Results: Indirect comparison methods are used in approximately 28% (23/81) of all HTA for incorporation into Brazil’s supplementary health system, and it is more frequently used in oncology and medicine assessments. Network meta-analysis is the most frequently adopted method [78% (18/23)], but specific frameworks for assessing the certainty of the evidence, such as GRADE-NMA 4% (1/23) and CINeMA 13% (3/23), were rarely used. As for incremental budget impact, it was lower in the HTA that used any type of indirect comparisons. Other agencies are facing an increase in indirect comparison for health technology assessment. Conclusions: Further efforts are necessary to evaluate the impact of indirect comparisons on recommendations and to better standardize the methodological approaches to indirect comparisons.
- 4 August 2026
- Published by HTA Unit - Inova Medical in HTA Journal
- Vol. 1 (1) , 32-40
Open AccessUse of indirect comparison in technology assessment in Brazilian supplementary health: meta-research
Introduction: Technologies already covered in health systems are the ideal comparators in the HTA process of new technologies, making a particular local challenge the finding of these specific head-to-head studies. In their absence, indirect comparisons are presented as alternatives, but the extent and characteristics of use are unknown. Objective: This study aims to quantify the use and characteristics of indirect comparison methods in reports of a Brazilian HTA agency. Methodology: A meta-research was conducted to analyze the frequency of use of different indirect comparison methods from the perspective of Brazil’s supplementary health system, and characteristics such as frequency of incorporation and preliminary recommendation, type of method, certainty-of-evidence assessment tool used, technology type, major clinical area, and budget impact of incorporation. The protocol was registered prospectively and is available at https://doi.org/10.17605/OSF.IO/3V8YP. Results: Indirect comparison methods are used in approximately 28% (23/81) of all HTA for incorporation into Brazil’s supplementary health system, and it is more frequently used in oncology and medicine assessments. Network meta-analysis is the most frequently adopted method [78% (18/23)], but specific frameworks for assessing the certainty of the evidence, such as GRADE-NMA 4% (1/23) and CINeMA 13% (3/23), were rarely used. As for incremental budget impact, it was lower in the HTA that used any type of indirect comparisons. Other agencies are facing an increase in indirect comparison for health technology assessment. Conclusions: Further efforts are necessary to evaluate the impact of indirect comparisons on recommendations and to better standardize the methodological approaches to indirect comparisons.
- Open Access
- 2 July 2025
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 65 (11) , 1339-1349
Therapeutic Use of Cannabis Derivatives and Their Analogs for Autism Spectrum Disorder: A Systematic Review
Autism spectrum disorders are characterized by some difficulties with social interactions and communication, atypical patterns of behavior, and unusual reactions to emotions. Studies have found promising results regarding the effects of cannabis on autism. We conducted a systematic review of randomized clinical trials on the effects of cannabis derivatives and their analogs for autism. This review was developed according to the Cochrane Handbook for Systematic Reviews of Interventions and reported according to PRISMA 2020. The protocol was prospectively published in the PROSPERO database (CRD42023468300). We included randomized controlled trials with autism‐diagnosed participants treated with any cannabis derivate or its analogs for therapeutic purposes. Two reviewers assessed titles and abstracts independently and potentially eligible full texts were assessed to confirm eligibility. After that, they extracted data using a standardized worksheet. Searches retrieved 1264 references, only 11 RCTs were included, four with available results for children/adolescents with autism. Five different cannabis presentations were tested. One trial pointed that cannabis may improve global assessment symptoms, but for other outcomes results were uncertain. No included study assessed quality of life. The certainty of evidence ranged from very low to low certainty for the assessed outcomes. Cannabis whole plant extract may improve global assessment symptoms, but the different cannabis presentations, outcome assessments and very low certainty of evidence from the included studies make it difficult to draw conclusions about cannabis for people with autism. This scenario of uncertainties impacts directly clinical practice and decision making.
- 2 July 2025
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 65 (11) , 1339-1349
Open AccessTherapeutic Use of Cannabis Derivatives and Their Analogs for Autism Spectrum Disorder: A Systematic Review
Autism spectrum disorders are characterized by some difficulties with social interactions and communication, atypical patterns of behavior, and unusual reactions to emotions. Studies have found promising results regarding the effects of cannabis on autism. We conducted a systematic review of randomized clinical trials on the effects of cannabis derivatives and their analogs for autism. This review was developed according to the Cochrane Handbook for Systematic Reviews of Interventions and reported according to PRISMA 2020. The protocol was prospectively published in the PROSPERO database (CRD42023468300). We included randomized controlled trials with autism‐diagnosed participants treated with any cannabis derivate or its analogs for therapeutic purposes. Two reviewers assessed titles and abstracts independently and potentially eligible full texts were assessed to confirm eligibility. After that, they extracted data using a standardized worksheet. Searches retrieved 1264 references, only 11 RCTs were included, four with available results for children/adolescents with autism. Five different cannabis presentations were tested. One trial pointed that cannabis may improve global assessment symptoms, but for other outcomes results were uncertain. No included study assessed quality of life. The certainty of evidence ranged from very low to low certainty for the assessed outcomes. Cannabis whole plant extract may improve global assessment symptoms, but the different cannabis presentations, outcome assessments and very low certainty of evidence from the included studies make it difficult to draw conclusions about cannabis for people with autism. This scenario of uncertainties impacts directly clinical practice and decision making.
- Open Access
- 20 May 2025
- Published by MPM Comunicacao in Saúde Coletiva (Barueri)
- Vol. 15 (95) , 15728-15751
Avaliação Situacional de Protocolos Assistenciais do SUS (ASPAS): Um Estudo de Inquérito
Os Protocolos Clínicos e Diretrizes Terapêuticas (PCDTs) são documentos que orientam o diagnóstico, tratamento e monitoramento de condições pelo Sistema Único de Saúde (SUS). O objetivo deste estudo foi identificar as percepções dos profissionais usuários dessas diretrizes nos Estados e Municípios. Trata-se de um estudo transversal. A amostra compreendeu secretários estaduais e municipais de saúde, gestores ligados à atenção especializada e regulação, superintendentes, diretores e coordenadores de assistência farmacêutica. Dados sociodemográficos dos participantes e suas percepções acerca da implementação de PCDT foram coletados via questionário online. 108 participantes completaram os questionários, declarando conhecer os PCDTs (99,1%, n=107) e confiar muito neles (86,1%, n=93). A maioria dos respondentes acredita haver barreiras para a implementação de diretrizes no SUS (84,6%, n=88), sendo as principais de infraestrutura, de recursos humanos e logística/financeira. Apesar da baixa adesão à pesquisa, este trabalho apresenta relevância para políticas públicas e contribui para suprir a escassez de estudos sobre a implementação de PCDTs.
- 20 May 2025
- Published by MPM Comunicacao in Saúde Coletiva (Barueri)
- Vol. 15 (95) , 15728-15751
Open AccessAvaliação Situacional de Protocolos Assistenciais do SUS (ASPAS): Um Estudo de Inquérito
Os Protocolos Clínicos e Diretrizes Terapêuticas (PCDTs) são documentos que orientam o diagnóstico, tratamento e monitoramento de condições pelo Sistema Único de Saúde (SUS). O objetivo deste estudo foi identificar as percepções dos profissionais usuários dessas diretrizes nos Estados e Municípios. Trata-se de um estudo transversal. A amostra compreendeu secretários estaduais e municipais de saúde, gestores ligados à atenção especializada e regulação, superintendentes, diretores e coordenadores de assistência farmacêutica. Dados sociodemográficos dos participantes e suas percepções acerca da implementação de PCDT foram coletados via questionário online. 108 participantes completaram os questionários, declarando conhecer os PCDTs (99,1%, n=107) e confiar muito neles (86,1%, n=93). A maioria dos respondentes acredita haver barreiras para a implementação de diretrizes no SUS (84,6%, n=88), sendo as principais de infraestrutura, de recursos humanos e logística/financeira. Apesar da baixa adesão à pesquisa, este trabalho apresenta relevância para políticas públicas e contribui para suprir a escassez de estudos sobre a implementação de PCDTs.
- Open Access
- 1 January 2025
- Published by Wiley in International Journal Of Clinical Practice
- Vol. 2025 (1)
Efficacy and Safety of Duloxetine for the Treatment of Osteoarthritis: Systematic Review and Meta‐Analysis
Background: Osteoarthritis (OA) is a common illness that is widespread globally, especially among individuals aged 65 and older. Since 2019/2020, the OARSI and ACR recommendations have included the use of medicines such duloxetine, which function as analgesics for pain patients including central sensitization. Recent studies have assessed duloxetine as an adjunctive treatment in decreasing OA pain. Objective: Assess the effectiveness and safety of duloxetine in treating OA pain in adults aged 40 and above. Methods: We conducted a systematic review and meta‐analysis of randomized clinical trials. The scientific evidence search was conducted in the following databases: MEDLINE via PubMed, Cochrane Library, Embase, LILACS, Web of Science, Scopus, CINAHL, ProQuest, SciELO, and Google Scholar. Findings: The systematic review comprised nine randomized controlled trials (RCTs). The studies showed that using duloxetine for OA treatment was more effective than a placebo in achieving a 50% pain reduction (RR = 1.57, 95% CI = 1.31; 1.89) and a 30% pain reduction (RR = 1.41; 95% CI = 1.29; 1.55). This improvement was observed in pain, physical function, and stiffness as measured by the WOMAC subscales, as well as in the CGI‐SEVERITY scale and the AUSCAN functional index. Duloxetine was found to be more effective than gabapentin and acetaminophen in treating moderate to severe knee OA, as it decreased ratings on the whole WOMAC scale and its subscales for pain, physical function, and stiffness. There was no statistically significant difference in adverse events between duloxetine and gabapentin, both of which were more effective than acetaminophen, which did not cause any adverse events. Conclusion: This systematic review indicates that duloxetine is an effective treatment for pain in OA in adult patients over 40 years old, with a reasonable level of safety when compared to other centrally acting medications and placebo.
- 1 January 2025
- Published by Wiley in International Journal Of Clinical Practice
- Vol. 2025 (1)
Open AccessEfficacy and Safety of Duloxetine for the Treatment of Osteoarthritis: Systematic Review and Meta‐Analysis
Background: Osteoarthritis (OA) is a common illness that is widespread globally, especially among individuals aged 65 and older. Since 2019/2020, the OARSI and ACR recommendations have included the use of medicines such duloxetine, which function as analgesics for pain patients including central sensitization. Recent studies have assessed duloxetine as an adjunctive treatment in decreasing OA pain. Objective: Assess the effectiveness and safety of duloxetine in treating OA pain in adults aged 40 and above. Methods: We conducted a systematic review and meta‐analysis of randomized clinical trials. The scientific evidence search was conducted in the following databases: MEDLINE via PubMed, Cochrane Library, Embase, LILACS, Web of Science, Scopus, CINAHL, ProQuest, SciELO, and Google Scholar. Findings: The systematic review comprised nine randomized controlled trials (RCTs). The studies showed that using duloxetine for OA treatment was more effective than a placebo in achieving a 50% pain reduction (RR = 1.57, 95% CI = 1.31; 1.89) and a 30% pain reduction (RR = 1.41; 95% CI = 1.29; 1.55). This improvement was observed in pain, physical function, and stiffness as measured by the WOMAC subscales, as well as in the CGI‐SEVERITY scale and the AUSCAN functional index. Duloxetine was found to be more effective than gabapentin and acetaminophen in treating moderate to severe knee OA, as it decreased ratings on the whole WOMAC scale and its subscales for pain, physical function, and stiffness. There was no statistically significant difference in adverse events between duloxetine and gabapentin, both of which were more effective than acetaminophen, which did not cause any adverse events. Conclusion: This systematic review indicates that duloxetine is an effective treatment for pain in OA in adult patients over 40 years old, with a reasonable level of safety when compared to other centrally acting medications and placebo.
- Open Access
- 21 February 2024
- Published by Universidade de São Paulo. Agência de Bibliotecas e Coleções Digitais in Revista de Saúde Pública
- Vol. 58 (1) , 16
Sínteses de evidências para apoio à tomada de decisões relacionadas à pandemia de covid-19
A pandemia de covid-19 gerou um numeroso volume de produções científicas com diferentes níveis de qualidade. A velocidade com que o conhecimento era produzido e compartilhado a nível mundial impôs à gestão em saúde o desafio de buscar meios de identificar as melhores evidências disponíveis para subsidiar suas decisões. Em resposta a este desafio, o Departamento de Ciência e Tecnologia do Ministério da Saúde do Brasil estabeleceu um serviço para elaborar e disponibilizar conhecimento científico abordando questões prioritárias de saúde pública no cenário da pandemia. Entre os temas abordados estão tratamentos medicamentosos, medidas não farmacológicas, testagem, reinfecção e resposta imunológica, imunização, fisiopatologia, síndrome pós-covid e eventos adversos. Neste artigo, discute-se os pontos fortes e lições aprendidas, bem como os desafios e perspectivas que fornecem um exemplo real sobre como disponibilizar as melhores evidências científicas, em tempo hábil e de forma oportuna, para auxiliar o processo decisório durante uma emergência em saúde pública.
- 21 February 2024
- Published by Universidade de São Paulo. Agência de Bibliotecas e Coleções Digitais in Revista de Saúde Pública
- Vol. 58 (1) , 16
Open AccessSínteses de evidências para apoio à tomada de decisões relacionadas à pandemia de covid-19
A pandemia de covid-19 gerou um numeroso volume de produções científicas com diferentes níveis de qualidade. A velocidade com que o conhecimento era produzido e compartilhado a nível mundial impôs à gestão em saúde o desafio de buscar meios de identificar as melhores evidências disponíveis para subsidiar suas decisões. Em resposta a este desafio, o Departamento de Ciência e Tecnologia do Ministério da Saúde do Brasil estabeleceu um serviço para elaborar e disponibilizar conhecimento científico abordando questões prioritárias de saúde pública no cenário da pandemia. Entre os temas abordados estão tratamentos medicamentosos, medidas não farmacológicas, testagem, reinfecção e resposta imunológica, imunização, fisiopatologia, síndrome pós-covid e eventos adversos. Neste artigo, discute-se os pontos fortes e lições aprendidas, bem como os desafios e perspectivas que fornecem um exemplo real sobre como disponibilizar as melhores evidências científicas, em tempo hábil e de forma oportuna, para auxiliar o processo decisório durante uma emergência em saúde pública.
- Open Access
- 30 October 2020
- Published by Wolters Kluwer Health in Medicine
- Vol. 99 (44) , e22915
Placebo use and outcome quality
Background: The Pharmaceutical industry sponsorship, research outcome and quality has been already evaluated for clinical trials in order to analyze if this kind of sponsorship affects the results of clinical trials. In this sense, this study has the aim to investigate whether placebo use allows positive outcomes regarding efficacy and safety compared to synthetic medicines. Methods: We designed and registered a study protocol for a systematic review for methodology data. We will only randomized clinical trials that use placebo as comparator. The main outcome will be the evaluation of placebo use regarding the tendency for positive results (efficacy and security) when comparing to synthetic medicines. PubMed, Cochrane, LILACS (BVS), Web of Science, Scopus, and Excerpta Medica dataBASE (EMBASE) databases will be searched. Gray literature will be identified through the databases Proquest (Dissertation and Theses), OpenGrey and Google Scholar. Two review authors will independently assess trial quality and will extract data in accordance with standard Cochrane methodology. If necessary, we will also contact authors for additional information. The Cochrane Collaboration's risk of bias tool will be used. If feasible, it means homogenous data, we will conduct random effects meta-analysis. Subgroup analyses will be conducted for different justifications for placebo use and for studies sponsored/not sponsored by the pharmaceutical industry. Results: Our present findings will indicate the effects of placebo use as comparator regarding efficacy and safety of the oral synthetic medicines. Discussion: This systematic review will identify, summarize, and analyze if there is a trend for positive efficacy and safety results for synthetic medicines in clinical trials when compared with placebo and if the justification for placebo use is considered ethically acceptable. Systematic review registration: PROSPERO CRD42018110829
- 30 October 2020
- Published by Wolters Kluwer Health in Medicine
- Vol. 99 (44) , e22915
Open AccessPlacebo use and outcome quality
Background: The Pharmaceutical industry sponsorship, research outcome and quality has been already evaluated for clinical trials in order to analyze if this kind of sponsorship affects the results of clinical trials. In this sense, this study has the aim to investigate whether placebo use allows positive outcomes regarding efficacy and safety compared to synthetic medicines. Methods: We designed and registered a study protocol for a systematic review for methodology data. We will only randomized clinical trials that use placebo as comparator. The main outcome will be the evaluation of placebo use regarding the tendency for positive results (efficacy and security) when comparing to synthetic medicines. PubMed, Cochrane, LILACS (BVS), Web of Science, Scopus, and Excerpta Medica dataBASE (EMBASE) databases will be searched. Gray literature will be identified through the databases Proquest (Dissertation and Theses), OpenGrey and Google Scholar. Two review authors will independently assess trial quality and will extract data in accordance with standard Cochrane methodology. If necessary, we will also contact authors for additional information. The Cochrane Collaboration's risk of bias tool will be used. If feasible, it means homogenous data, we will conduct random effects meta-analysis. Subgroup analyses will be conducted for different justifications for placebo use and for studies sponsored/not sponsored by the pharmaceutical industry. Results: Our present findings will indicate the effects of placebo use as comparator regarding efficacy and safety of the oral synthetic medicines. Discussion: This systematic review will identify, summarize, and analyze if there is a trend for positive efficacy and safety results for synthetic medicines in clinical trials when compared with placebo and if the justification for placebo use is considered ethically acceptable. Systematic review registration: PROSPERO CRD42018110829
- Open Access
- 1 September 2020
- Published by FapUNIFESP (SciELO) in Ciencia & Saude Coletiva
- Vol. 25 (9) , 3517-3554
Terapia medicamentosa para infecções por coronavírus em humanos: revisão sistemática rápida
Resumo O objetivo deste trabalho foi avaliar efeitos de tratamentos medicamentosos para infecções por coronavírus. Revisão sistemática rápida com buscas nas bases MEDLINE, EMBASE, Cochrane, BVS, Global Index Medicus, Medrix, bioRxiv, Clinicaltrials.gov e International Clinical Trials Registry Platform. Foram incluídos 36 estudos avaliando alternativas medicamentosas contra SARS, SARS-CoV-2 e MERS. A maioria dos estudos incluídos foi conduzida na China com delineamento observacional para tratamento da COVID-19. Os tratamentos mais estudados foram antimaláricos e antivirais. Nos antimaláricos, a metanálise de dois estudos com 180 participantes não identificou benefício da hidroxicloroquina em relação à negativação da carga viral via reação em cadeia de polimerase em tempo real e o uso de antivirais comparado ao cuidado padrão foi similar em relação aos desfechos. As evidências científicas disponíveis são preliminares e de baixa qualidade metodológica, o que sugere cautela na interpretação dos dados. Pesquisas que avaliem a eficácia comparativa em ensaios clínicos randomizados, controlados, com tempo de acompanhamento adequado e com os métodos devidamente divulgados e sujeitos à revisão científica por pares são necessárias. Recomenda-se atualização periódica da presente revisão.
- 1 September 2020
- Published by FapUNIFESP (SciELO) in Ciencia & Saude Coletiva
- Vol. 25 (9) , 3517-3554
Open AccessTerapia medicamentosa para infecções por coronavírus em humanos: revisão sistemática rápida
Resumo O objetivo deste trabalho foi avaliar efeitos de tratamentos medicamentosos para infecções por coronavírus. Revisão sistemática rápida com buscas nas bases MEDLINE, EMBASE, Cochrane, BVS, Global Index Medicus, Medrix, bioRxiv, Clinicaltrials.gov e International Clinical Trials Registry Platform. Foram incluídos 36 estudos avaliando alternativas medicamentosas contra SARS, SARS-CoV-2 e MERS. A maioria dos estudos incluídos foi conduzida na China com delineamento observacional para tratamento da COVID-19. Os tratamentos mais estudados foram antimaláricos e antivirais. Nos antimaláricos, a metanálise de dois estudos com 180 participantes não identificou benefício da hidroxicloroquina em relação à negativação da carga viral via reação em cadeia de polimerase em tempo real e o uso de antivirais comparado ao cuidado padrão foi similar em relação aos desfechos. As evidências científicas disponíveis são preliminares e de baixa qualidade metodológica, o que sugere cautela na interpretação dos dados. Pesquisas que avaliem a eficácia comparativa em ensaios clínicos randomizados, controlados, com tempo de acompanhamento adequado e com os métodos devidamente divulgados e sujeitos à revisão científica por pares são necessárias. Recomenda-se atualização periódica da presente revisão.